Home Cart Sign in  
Chemical Structure| 1243244-14-5 Chemical Structure| 1243244-14-5

Structure of LGK974
CAS No.: 1243244-14-5

Chemical Structure| 1243244-14-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LGK974 (WNT974) is an orally bioavailable and specific Porcupine (PORCN) inhibitor with an IC50 of 0.1 nM.

Synonyms: WNT974; PORCN Inhibitor IV; NVP-LGK974

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LGK974

CAS No. :1243244-14-5
Formula : C23H20N6O
M.W : 396.44
SMILES Code : O=C(NC1=NC=C(C2=NC=CN=C2)C=C1)CC3=CN=C(C4=CC(C)=NC=C4)C(C)=C3
Synonyms :
WNT974; PORCN Inhibitor IV; NVP-LGK974
MDL No. :MFCD27501026
InChI Key :XXYGTCZJJLTAGH-UHFFFAOYSA-N
Pubchem ID :46926973

Safety of LGK974

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
LGK974, known as WNT974, represents a highly specific and orally bioavailable inhibitor of Porcupine (PORCN), a key enzyme involved in the post-translational modification of Wnt proteins, with an impressive IC50 of 0.1 nM[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
VCaP cells 0.5–1.0 μM 19 hours To assess the effects of LGK974 on WNT pathway activity, results showed that LGK974 significantly reduced the expression of WNT/β-catenin-regulated proteins MYC, cyclin D1, and LEF1 PMC4855922
BRPS organoids 500 nM 4 days LGK974 treatment significantly reduced proliferation and promoted differentiation PMC5508203
HEK-293S GnTI− cells 10 μM 30 minutes To measure the acyltransferase activity of PORCN and validate the inhibitory effect of LGK974 on PORCN. PMC9404457
KPT-LUAD cells 100 nM one week To assess the effect of CD:LGK974 complexes on Wnt signaling inhibition in KPT-LUAD cells, results showed that CD:LGK974 complexes significantly suppressed Wnt signaling activation. PMC6441337

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice C57/BL6 mouse model Oral 1-30 mg/kg Daily administration for 4 weeks To evaluate the effects of LGK974 on bone volume and density, results showed that LGK974 led to significant reduction in bone volume and density. PMC5968037
mice VCaP xenograft model intraperitoneal injection 3 mg/kg once daily for 17 days To evaluate the effect of LGK974 on tumor growth in a SOX9-expressing prostate cancer xenograft model, results showed that LGK974 significantly suppressed tumor growth PMC4855922
mice R26-rtTA/c3GIC9-E-Rspo2 and R26-rtTA/c3GIC9-P-Rspo3 bi-transgenic mice oral 5 mg/kg once daily for 7 days LGK974 treatment completely abolished E-Rspo2 lesions and significantly reduced tumour burden in P-Rspo3 mice PMC5508203
Mice LPS-induced endotoxemia model Intraperitoneal injection 0-60 mg/kg Single injection, 2 hours before, simultaneously with, or 1 hour after LPS injection LGK974 significantly and dose-dependently increased the survival rate and reduced plasma cytokine levels in mice with LPS-induced endotoxemia. LGK974 treatment suppressed the activation of NF-κB signaling and cytokine expression as well as the Wnt/β-catenin pathway in the livers of endotoxemic mice. PMC8080716
mice lung cancer allograft model oral 10 mg/kg/d once daily for 7 days To evaluate the effect of CD:LGK974 complexes on Wnt signaling inhibition and intestinal toxicity in a mouse lung cancer allograft model, results showed that CD:LGK974 complexes significantly inhibited Wnt signaling and reduced intestinal toxicity. PMC6441337
Mice Patient-derived xenograft (PDX) model Intraperitoneal injection 3 mg/kg Every day The combination of LGK974 with Cetuximab significantly inhibited the growth of high CHD6-expressing CRC PDX tumors, reduced TMEM65 expression, increased cleaved caspase-3 expression, and decreased Ki67 expression. PMC9727023
Mice CT2A and RCAS/tv-a glioma models Gavage 150 mg or 300 mg Twice daily, continued until postpartum To investigate the effect of LGK974 on TMZ penetration in tumors, results showed that LGK974 treatment increased TMZ penetration in both CT2A and RCAS/tv-a glioma models and improved mouse survival. PMC10237416

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02649530 Squamous Cell Carcinoma, Head ... More >>And Neck Less << PHASE2 WITHDRAWN - University of Michigan Compreh... More >>ensive Cancer Center, Ann Arbor, Michigan, 48109, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.52mL

0.50mL

0.25mL

12.61mL

2.52mL

1.26mL

25.22mL

5.04mL

2.52mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories